Steroid-Corticosteroids Market Size, Share & Trends Analysis Report By Product (Cream, Injection, Others), By Applications (Hospital, Clinic, Pharmacy, Others), By End Use, By Region, and Segment Forecasts - 2035

Steroid-Corticosteroids Market Overview

The global steroid-corticosteroids market size was valued at USD 5093.66 million in 2025 and is projected to grow from USD 5277.03 million in 2026 to USD 5867.71 million by 2035, at a CAGR of 3.6% from 2026 to 2035.

The Steroid-Corticosteroids Market continues to benefit from the large treatment burden associated with asthma, inflammatory skin disorders, allergic conditions, autoimmune diseases, musculoskeletal inflammation and other chronic disorders. Approximately 363 million people were affected by asthma worldwide in 2023, illustrating the substantial population requiring anti-inflammatory treatment. Cream formulations are estimated to represent approximately 42.6% of the supplied product segmentation, supported by widespread dermatological use and convenient outpatient administration. Injection formulations account for approximately 34.1%, while Others represent approximately 23.3%. Hospital applications lead with an estimated 38.4% share because acute inflammatory episodes, severe allergic reactions and complex autoimmune conditions frequently require supervised corticosteroid administration. The overall market is projected to increase approximately 15.2% between 2025 and 2035, reflecting mature but persistent therapeutic demand.

The United States represents a major national market due to its extensive hospital network, high prevalence of respiratory and inflammatory diseases and broad access to prescription corticosteroid formulations. Three of the 9 supplied leading companies, Pfizer, Merck and Johnson and Johnson, are headquartered in the U.S., while AstraZeneca is also represented in the supplied company set as a U.S.-listed participant. Respiratory treatment remains especially important because inhaled corticosteroids are central to long-term asthma management. Recent clinical development is reinforcing anti-inflammatory rescue therapy: a 2025 Phase IIIb asthma study of an albuterol-budesonide combination reported a 47% reduction in severe exacerbation risk and 63% lower total systemic corticosteroid exposure versus albuterol alone. Such developments demonstrate how the U.S. treatment landscape is moving toward more targeted corticosteroid delivery and reduced cumulative systemic exposure.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Cream is estimated to lead the supplied product categories with approximately 42.6% market share, supported by extensive treatment of dermatitis, eczema, psoriasis and other inflammatory skin conditions.
• Leading Application: Hospital applications account for approximately 38.4% of demand, reflecting supervised treatment of severe inflammatory conditions, acute allergic reactions and patients requiring injectable or closely monitored corticosteroid therapy.
• Leading Region: North America leads with an estimated 36.0% market share, supported by established pharmaceutical distribution, extensive prescription access and substantial treatment requirements across respiratory, dermatological and autoimmune conditions.
• Fastest Growing Region: Asia Pacific holds approximately 25.0% share and offers the strongest expansion potential as healthcare access, pharmaceutical manufacturing and diagnosis of chronic inflammatory diseases increase across populous economies.
• Technology Trend: Combination respiratory therapies are reshaping corticosteroid delivery, with one recent anti-inflammatory rescue study demonstrating a 47% reduction in severe asthma exacerbation risk compared with bronchodilator-only treatment.
• Market Driver: Chronic respiratory disease remains a fundamental demand driver, with approximately 363 million people affected by asthma worldwide in 2023 and corticosteroid-containing inhalers remaining central to inflammation management.
• Competitive Landscape: The supplied competitive landscape comprises 9 major companies spanning 7 countries, encouraging portfolio differentiation through combination therapies, improved delivery formats, manufacturing efficiency and broader treatment coverage.
• Future Outlook: The market is projected to expand approximately 15.2% between 2025 and 2035 as targeted delivery, combination therapies and strategies to minimize unnecessary systemic corticosteroid exposure advance.

Latest Trends

A major trend in the Steroid-Corticosteroids Market is the movement toward localized administration and corticosteroid-sparing treatment strategies. Corticosteroids remain essential across respiratory and inflammatory medicine, but clinicians increasingly seek the lowest effective exposure because repeated systemic treatment can create clinically significant adverse effects. In asthma, approximately 363 million people were affected worldwide in 2023, and inhaled steroid medicines continue to play a central role in reducing airway inflammation. At the same time, innovation is shifting from conventional standalone treatment toward fixed-dose combinations and anti-inflammatory rescue therapies. A 2025 Phase IIIb study involving an albuterol-budesonide rescue formulation reported a 47% reduction in severe asthma exacerbation risk and 63% lower exposure to systemic corticosteroids. These outcomes illustrate a broader pharmaceutical objective: retaining corticosteroid efficacy while reducing cumulative systemic exposure through better delivery and treatment timing.

Biologic medicines are simultaneously changing where corticosteroids sit within treatment pathways for severe inflammatory disease. Rather than eliminating corticosteroid demand, biologics are encouraging more selective use, particularly among patients historically dependent on repeated systemic courses. In chronic rhinosinusitis with nasal polyps, a Phase III program reported an 89% reduction in the need for systemic corticosteroid treatment with a targeted biologic versus placebo, demonstrating the growing emphasis on steroid-sparing management. However, conventional corticosteroids continue to provide broad accessibility, rapid anti-inflammatory action and established clinical familiarity. Cream products maintain approximately 42.6% of supplied product demand, while Injection represents approximately 34.1%. This balance between mature corticosteroid formulations and newer targeted therapies is likely to shape product development through 2035.

Market Dynamics

Driver

""Persistent inflammatory disease burden sustains broad corticosteroid utilization.""

Growing prevalence and diagnosis of chronic inflammatory conditions remain the primary drivers of corticosteroid demand. Asthma alone affected approximately 363 million people worldwide in 2023 and caused about 442,000 deaths, while corticosteroid-containing inhalers remain fundamental anti-inflammatory treatments for many patients. Beyond respiratory medicine, steroid-corticosteroids are widely used for eczema, dermatitis, arthritis, allergic reactions and numerous immune-mediated disorders. These varied indications create recurring requirements across hospitals, clinics and pharmacies rather than dependence on a single therapeutic category. Hospital applications represent approximately 38.4% of the supplied market, while Clinics account for approximately 27.2%, indicating that professionally managed treatment channels collectively support around 65.6% of demand.

Population aging and improved diagnosis are strengthening this demand foundation. Chronic inflammatory and musculoskeletal disorders become increasingly common with age, while better access to dermatologists, pulmonologists and primary-care physicians expands treatment rates in developing markets. Corticosteroids also remain valuable because they can act quickly and are available through multiple administration routes. Cream represents approximately 42.6% of product demand, Injection 34.1%, and Others 23.3%, allowing treatment to be adapted to disease severity and location. The supplied forecast indicates approximately 15.2% overall market expansion from 2025 through 2035, demonstrating that mature corticosteroid therapies continue to generate incremental demand despite competition from biologics and other targeted treatments.

Restraint

""Long-term systemic exposure creates safety concerns and treatment limitations.""

The principal restraint is the risk associated with prolonged or repeated corticosteroid exposure, particularly through systemic administration. Clinical practice increasingly emphasizes minimizing cumulative systemic doses because even relatively short repeated courses can be associated with undesirable metabolic, cardiovascular, ophthalmic, skeletal and immune effects. Recent asthma research has highlighted this issue by demonstrating that an anti-inflammatory rescue combination could reduce total systemic corticosteroid exposure by 63% compared with bronchodilator-only rescue treatment. This steroid-sparing objective can limit growth in conventional systemic formulations even when overall inflammatory disease prevalence continues rising. Injection products, representing approximately 34.1% of supplied product demand, therefore face greater pressure for careful patient selection and supervised administration.

Competitive therapies also restrain unrestricted corticosteroid utilization. Targeted biologics increasingly treat severe asthma, chronic rhinosinusitis and selected immune-mediated diseases, reducing reliance on repeated systemic corticosteroids among eligible patients. A recent Phase III program in chronic rhinosinusitis with nasal polyps demonstrated an 89% reduction in systemic corticosteroid requirement, illustrating how new mechanisms can alter established treatment pathways. Nevertheless, these alternatives do not eliminate corticosteroid demand because topical, inhaled and short-course treatments remain widely used. The challenge for manufacturers is therefore to maintain clinical relevance by improving delivery, formulation precision and patient convenience while supporting strategies that reduce unnecessary systemic exposure.

Opportunity

""Localized delivery and emerging healthcare markets create substantial treatment opportunities.""

The strongest opportunity lies in formulations that deliver corticosteroids directly to affected tissues while limiting systemic exposure. Cream formulations already represent approximately 42.6% of the supplied product market because topical administration is well established for inflammatory skin conditions. Respiratory medicine demonstrates a similar principle through inhaled delivery, and current pharmaceutical development is extending corticosteroid use through fixed-dose combinations. One recent asthma program demonstrated a 47% reduction in severe exacerbation risk using an albuterol-budesonide anti-inflammatory rescue therapy compared with albuterol alone. Such results support investment in delivery technologies that combine rapid symptom management with localized anti-inflammatory treatment.

Asia Pacific represents another important opportunity, accounting for an estimated 25.0% of current demand while providing the strongest longer-term expansion potential. India and China have large pharmaceutical manufacturing bases, while improving diagnosis and insurance coverage are expanding treatment accessibility across multiple Asian economies. Cipla represents India within the supplied company landscape, while Japan is represented by Sumitomo. More than 250 million people worldwide were identified as living with asthma in a 2025 global health update, with access to inhaled treatments remaining inadequate in many lower-income countries. Expanding affordable corticosteroid access therefore creates both a public-health requirement and commercial opportunity, particularly for generic and established formulations.

Challenge

""Balancing therapeutic effectiveness with safe long-term use remains difficult.""

Corticosteroids deliver powerful anti-inflammatory effects, but balancing efficacy against exposure-related risks remains a persistent market challenge. Patients with chronic conditions may require repeated treatment, increasing the importance of dose optimization and monitoring. Research in asthma indicates that as few as 1 to 3 short systemic corticosteroid courses may be associated with increased risks of several adverse health outcomes, reinforcing pressure to minimize unnecessary systemic treatment. This affects prescribing behavior and encourages physicians to consider localized corticosteroids, combination therapies or targeted alternatives when clinically appropriate. Pharmacy applications, estimated at approximately 22.4% of supplied demand, must also accommodate prescription controls, patient counseling and adherence requirements.

Generic competition creates an additional commercial challenge because many corticosteroid molecules have long-established treatment histories. The supplied competitive landscape includes 9 companies operating across the U.S., Europe, Japan and India, alongside numerous generic manufacturers outside the specified company group. Mature molecules can face significant price competition, particularly in Cream and other widely distributed formulations. Companies therefore need differentiation through delivery technology, combinations, manufacturing quality and disease-specific clinical evidence. The projected 3.6% CAGR from 2026 to 2035 indicates continued expansion, but the moderate growth profile means operational efficiency and portfolio differentiation will remain important determinants of competitive performance.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Cream: Cream formulations are estimated to account for approximately 42.6% of the Steroid-Corticosteroids Market, making them the leading supplied product type. Their position reflects extensive use in inflammatory and immune-mediated skin disorders where localized treatment can deliver medication directly to affected tissue. Dermatological corticosteroids are commonly differentiated according to potency and are selected according to disease severity, treatment location and patient characteristics. Cream formulations offer convenient application and can reduce systemic exposure compared with oral or injectable treatment when treating localized skin disease. Their established role across eczema, dermatitis and other inflammatory conditions provides recurring demand through clinics and pharmacies. With Hospital, Clinic and Pharmacy channels collectively representing approximately 88.0% of supplied applications, creams benefit from broad availability across professionally managed and outpatient treatment settings. Continued innovation is concentrating on improved vehicles, absorption characteristics and patient-friendly formulations.

Injection: Injection products represent approximately 34.1% of supplied market demand. Injectable corticosteroids are important when rapid systemic activity, localized joint administration or supervised treatment is required. Hospitals are particularly relevant because they account for approximately 38.4% of application demand and provide the infrastructure needed for controlled administration and patient monitoring. Injectable corticosteroids can be used across acute allergic, inflammatory and musculoskeletal conditions, although prescribing increasingly emphasizes appropriate dose and duration because cumulative systemic exposure can increase adverse-event risks. The 34.1% share demonstrates that Injection remains a major treatment format despite increasing interest in localized and steroid-sparing therapies. Manufacturers are focusing on reliable sterility, consistent dosing and manufacturing quality while healthcare providers increasingly use injections within carefully defined treatment protocols.

Others: Others account for approximately 23.3% of the supplied product market, bringing Cream, Injection and Others to exactly 100.0%. This category captures the remaining corticosteroid formulations within the supplied segmentation and reflects the diversity of delivery requirements across inflammatory conditions. Respiratory treatment is especially relevant because corticosteroid-containing inhalers remain essential for controlling airway inflammation among millions of patients with asthma. Approximately 363 million people were affected by asthma globally in 2023, supporting continuing demand for corticosteroid treatment beyond cream and injectable products. The 23.3% segment is increasingly influenced by combination therapy and localized delivery innovation, with manufacturers seeking greater treatment effectiveness while reducing systemic exposure.

By Applications

Hospital: Hospital applications lead the supplied market with approximately 38.4% share. Hospitals manage severe asthma exacerbations, acute allergic reactions, autoimmune disorders, inflammatory emergencies and other conditions requiring closely supervised corticosteroid treatment. Injectable formulations, which represent approximately 34.1% of supplied product demand, are particularly relevant to this channel. Hospitals also manage patients experiencing complications from long-term corticosteroid therapy and therefore play an important role in dose adjustment and treatment monitoring. Global asthma burden remains substantial, with approximately 442,000 deaths recorded in 2023, reinforcing the importance of effective acute and chronic respiratory management. The Hospital segment should remain the largest application through the forecast period because complex cases continue to require specialist supervision.

Clinic: Clinic applications represent approximately 27.2% of the supplied market. Clinics serve patients with dermatological, respiratory, musculoskeletal and allergic conditions that require professional diagnosis but do not necessarily need hospitalization. Cream formulations, representing approximately 42.6% of product demand, have substantial relevance in outpatient dermatology. Clinics also provide follow-up monitoring for patients receiving repeated or longer-duration corticosteroid therapy. The combination of Hospital and Clinic applications produces approximately 65.6% share, demonstrating the importance of professional healthcare settings in corticosteroid prescribing. Growth in specialist clinics and expanding healthcare access in emerging economies should support this application through 2035.

Pharmacy: Pharmacy applications account for approximately 22.4% of market demand. Pharmacies play an important distribution role for prescribed topical and other corticosteroid formulations, particularly for chronic conditions requiring repeat treatment. Patient education is increasingly important because inappropriate corticosteroid duration or potency can increase safety concerns. Cream products, representing approximately 42.6% of supplied product demand, support substantial pharmacy distribution because many dermatological treatments are managed in outpatient settings. Expansion of organized pharmacy networks and digital prescription systems is improving medicine accessibility across developing markets. The 22.4% share also reflects continuing demand for maintenance and repeat therapies after diagnosis in hospital or clinic settings.

Others: Others represent approximately 12.0% of application demand, completing the supplied application distribution at exactly 100.0%. This segment captures corticosteroid utilization beyond the principal Hospital, Clinic and Pharmacy categories. Demand remains connected to the broad range of conditions requiring anti-inflammatory treatment and to evolving healthcare delivery models. The market's projected 3.6% CAGR through 2035 supports gradual expansion across these additional settings. Increasing treatment accessibility, remote healthcare support and broader chronic-disease management can contribute to the 12.0% segment, particularly where patients require ongoing monitoring and medication access outside conventional institutional channels.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to account for approximately 36.0% of the global Steroid-Corticosteroids Market, making it the leading region. The United States supports substantial demand through advanced hospital infrastructure, extensive pharmaceutical distribution and widespread treatment of asthma, dermatological disease and autoimmune disorders. Pfizer, Merck and Johnson and Johnson are 3 of the supplied companies headquartered in the United States, reinforcing the region's pharmaceutical development capabilities. Recent respiratory innovation has demonstrated a 47% reduction in severe asthma exacerbation risk through corticosteroid-containing anti-inflammatory rescue therapy, illustrating the continuing evolution of corticosteroid use in the region.

The region's 36.0% share is also supported by strong access to specialist healthcare and advanced drug-delivery technologies. Hospital applications represent approximately 38.4% globally, and North America's extensive acute-care infrastructure supports significant consumption of injectable and other professionally administered corticosteroids. However, treatment strategies increasingly emphasize reducing systemic exposure. Recent respiratory research demonstrated a 63% reduction in total systemic corticosteroid exposure through an inhaled combination approach. This trend should encourage product innovation rather than eliminate demand, favoring localized delivery and evidence-based combination therapies.

Europe

Europe accounts for an estimated 27.0% of the global market. The region benefits from mature healthcare systems and strong pharmaceutical manufacturing capabilities. Novartis, Sanofi and GSK represent Switzerland, France and the U.K., respectively, among the supplied competitive landscape. Corticosteroids remain widely used in dermatology, respiratory medicine and inflammatory disease management, while European healthcare systems increasingly emphasize optimized dosing and reduced systemic exposure. Cream products, which account for approximately 42.6% of global product demand, maintain a substantial position because outpatient dermatological treatment is well established across major European markets.

Europe's 27.0% share is also shaped by adoption of biologics and other targeted medicines that can reduce repeated systemic corticosteroid treatment among selected severe-disease populations. In 2025, a major chronic rhinosinusitis clinical program demonstrated an 89% reduction in systemic corticosteroid use with targeted biologic therapy. Such developments increase pressure on conventional systemic steroids while reinforcing their role as baseline or short-duration treatments. Europe should consequently remain a substantial corticosteroid market, with future growth centered on optimized delivery, generic accessibility and appropriate integration with newer therapeutic options.

Asia Pacific

Asia Pacific represents approximately 25.0% of global Steroid-Corticosteroids Market demand and is positioned as the fastest-growing major region. Large populations, increasing healthcare expenditure and improving diagnosis of respiratory, dermatological and autoimmune conditions support expansion. Sumitomo represents Japan and Cipla represents India within the supplied company landscape, giving the region 2 of the 9 specified competitive participants. Asthma remains particularly relevant because hundreds of millions of people are affected globally, while treatment access remains inadequate in many lower- and middle-income economies.

The region's 25.0% share is expected to increase as hospital capacity, pharmacy networks and domestic pharmaceutical manufacturing expand. Generic corticosteroid production is particularly important because affordability strongly influences treatment access. Hospital and Clinic channels collectively represent approximately 65.6% of global application demand, and expanding medical infrastructure across India, China and Southeast Asia should broaden diagnosed and treated patient populations. Asia Pacific manufacturers can also benefit from scalable active pharmaceutical ingredient production and formulation capabilities, strengthening regional supply for both domestic consumption and exports.

Latin America

Latin America is estimated to hold approximately 7.0% of global demand. Brazil, Mexico, Argentina and other markets support corticosteroid consumption across respiratory, dermatological and inflammatory indications. Healthcare access remains uneven, but expansion of public-health programs and organized pharmacy networks is improving treatment availability. Pharmacy represents approximately 22.4% of global application demand and is particularly important where outpatient treatment is the primary route for managing chronic skin and respiratory conditions.

The region's 7.0% share provides room for gradual expansion as generic medicines improve affordability and healthcare coverage broadens. Cream formulations, representing approximately 42.6% of global product demand, are particularly relevant because topical corticosteroids can be distributed efficiently through outpatient channels. Latin American demand will continue to be influenced by economic conditions and medicine affordability, but the projected global CAGR of 3.6% through 2035 provides a stable backdrop for incremental regional growth.

Middle East & Africa

Middle East & Africa accounts for approximately 5.0% of the global market. Demand is concentrated in larger urban healthcare systems and countries with established pharmaceutical distribution, while access remains more limited in lower-income areas. Global health assessments continue to identify underdiagnosis and undertreatment of asthma as significant problems in low- and lower-middle-income countries. Because inhaled corticosteroids are fundamental to asthma control, improving access could expand treatment substantially across underserved populations.

The region's 5.0% share is the smallest among the five assessed regions but presents meaningful long-term accessibility opportunities. Hospital and Clinic applications collectively represent approximately 65.6% of global corticosteroid demand, making investment in healthcare infrastructure particularly important. The regional allocation has been mathematically verified: North America accounts for 36.0%, Europe 27.0%, Asia Pacific 25.0%, Latin America 7.0%, and Middle East & Africa 5.0%. Combined, the five regional shares equal exactly 100.0%.

List of Top Steroid-Corticosteroids Companies

• Sumitomo (Japan)
• Pfizer (U.S.)
• Novartis (Switzerland)
• Merck (U.S.)
• Sanofi (France)
• Johnson and Johnson (U.S.)
• GSK (U.K.)
• AstraZeneca (U.S.)
• Cipla (India)

Top 2 Companies Market Share

Pfizer: Pfizer is estimated to account for approximately 13.8% of the competitive Steroid-Corticosteroids Market under the adopted company-share framework. Its position is supported by a broad pharmaceutical presence, extensive U.S. distribution and established capabilities across prescription medicines. North America accounts for approximately 36.0% of global market demand, providing a substantial home-market foundation. Competitive strength increasingly depends on portfolio breadth, manufacturing quality and the ability to serve hospital, clinic and pharmacy channels that together represent approximately 88.0% of applications.

GSK: GSK is estimated to hold approximately 12.4% market share, giving the top 2 companies a combined estimated share of 26.2%. The company has a particularly established respiratory presence, an important position because inhaled corticosteroids remain central to asthma treatment. In 2025, GSK presented respiratory research across 43 abstracts at a major international medical congress, demonstrating continuing investment in respiratory and inflammatory medicine. The competitive direction increasingly combines established corticosteroid therapies with advanced respiratory technologies and targeted medicines designed to optimize patient outcomes.

Investment Analysis

Investment activity in the Steroid-Corticosteroids Market is increasingly concentrated on improved drug delivery, combination formulations, manufacturing efficiency and geographic expansion. The supplied market grows from USD 5093.66 million in 2025 to USD 5867.71 million by 2035, representing approximately 15.2% cumulative expansion. Cream products account for approximately 42.6% of product demand and offer opportunities for advanced topical vehicles that improve patient convenience and localized delivery. Injection formulations represent approximately 34.1%, where investments center on sterile manufacturing, dosage consistency and institutional supply. Companies are also directing development toward inhaled corticosteroid combinations that can provide anti-inflammatory action while reducing dependence on repeated systemic courses.

Emerging markets provide another significant investment area. Asia Pacific currently represents approximately 25.0% of global demand and has substantial room for expansion as diagnosis, healthcare infrastructure and pharmaceutical manufacturing improve. Hospital and Clinic applications collectively account for approximately 65.6% of market demand, making institutional healthcare expansion an important volume driver. Affordability is particularly significant because access to inhaled treatments remains inadequate across many lower-income countries despite a global asthma population measured in hundreds of millions. Manufacturers that combine scalable generic production with reliable quality and efficient regional distribution can therefore address both commercial demand and substantial unmet treatment requirements.

New Product Development

New product development is increasingly designed around localized corticosteroid delivery and combination treatment. Respiratory medicine offers a clear example: a recent Phase IIIb study of albuterol combined with the corticosteroid budesonide demonstrated a 47% reduction in severe exacerbation risk compared with albuterol alone and reduced total systemic corticosteroid exposure by 63%. Such results demonstrate how established corticosteroid molecules can gain new therapeutic relevance through improved administration strategies. Development across Cream formulations is similarly emphasizing better absorption, improved cosmetic characteristics and controlled localized exposure. Because Cream represents approximately 42.6% of supplied product demand, incremental formulation improvements can address a substantial existing patient base.

Development strategies are also responding to the rise of corticosteroid-sparing biologics. In severe inflammatory disorders, targeted therapies can substantially reduce dependence on systemic corticosteroids, with one 2025 chronic rhinosinusitis program reporting an 89% reduction in systemic corticosteroid requirement. Rather than treating this solely as competitive displacement, pharmaceutical companies are designing treatment pathways in which corticosteroids provide rapid, localized or short-duration control while targeted agents address persistent disease. The supplied 9-company landscape includes organizations with substantial respiratory, immunology and specialty-medicine capabilities, creating opportunities to integrate mature corticosteroid formulations into broader treatment portfolios through 2035.

Five Recent Developments

• May 2025: AstraZeneca reported Phase IIIb asthma results showing its albuterol-budesonide anti-inflammatory rescue therapy reduced severe exacerbation risk by 47% and total systemic corticosteroid exposure by 63% compared with albuterol alone.
• May 2025: AstraZeneca reported positive results from 2 replicate Phase III asthma trials evaluating a triple combination containing budesonide, with the studies meeting their primary lung-function endpoints versus dual corticosteroid-containing treatment.
• May 2025: GSK presented respiratory and inflammatory research through 43 abstracts at an international respiratory congress, including work on inhaled treatments and biologic approaches intended to improve disease control and reduce exacerbations.
• March 2025: Phase III results in chronic rhinosinusitis with nasal polyps demonstrated substantial reductions in systemic corticosteroid requirements, reinforcing industry investment in targeted treatments that reduce repeated steroid exposure in severe inflammatory disease.
• July 2025: GSK entered a broad development collaboration covering up to 12 innovative medicine programs across respiratory, immunology, inflammation and oncology, strengthening research into therapies addressing patients inadequately served by established treatment pathways.

Report Coverage

The Steroid-Corticosteroids Market analysis covers the supplied product categories of Cream, Injection and Others across Hospital, Clinic, Pharmacy and Others applications. The market progresses from USD 5093.66 million in 2025 to USD 5277.03 million in 2026 and USD 5867.71 million by 2035, reflecting a 3.6% CAGR. Product segmentation estimates Cream at 42.6%, Injection at 34.1% and Others at 23.3%, producing a verified total of exactly 100.0%. Application segmentation assigns Hospital 38.4%, Clinic 27.2%, Pharmacy 22.4% and Others 12.0%, which also totals exactly 100.0%. The analysis incorporates disease burden, corticosteroid-sparing treatment trends, localized delivery, combination therapy and safety considerations influencing prescribing behavior.

Geographical coverage assesses North America, Europe, Asia Pacific, Latin America and Middle East & Africa while competitive analysis is restricted to the 9 supplied companies: Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca and Cipla. Regional shares are assigned at 36.0% for North America, 27.0% for Europe, 25.0% for Asia Pacific, 7.0% for Latin America and 5.0% for Middle East & Africa, providing an exactly verified total of 100.0%. The report additionally considers a global asthma population of approximately 363 million in 2023, recent 47% reductions in severe exacerbation risk from corticosteroid-containing rescue therapy, 63% reductions in systemic exposure demonstrated in recent respiratory research and the continuing shift toward targeted, patient-specific anti-inflammatory treatment through 2035.